These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 36537806)

  • 1. Antimicrobial Activity of Tannic Acid
    Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
    Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.
    Tanaka Y; Tashiro S; Ikegami S; Enoki Y; Taguchi K; Matsumoto K
    Anaerobe; 2023 Dec; 84():102789. PubMed ID: 37879532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clostridioides difficile Biofilm.
    Vuotto C; Donelli G; Buckley A; Chilton C
    Adv Exp Med Biol; 2024; 1435():249-272. PubMed ID: 38175479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.
    Wang S; Heuler J; Wickramage I; Sun X
    Microbiol Spectr; 2022 Apr; 10(2):e0178821. PubMed ID: 35315695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The
    Wickramage I; Peng Z; Chakraborty S; Harmanus C; Kuijper EJ; Alrabaa S; Smits WK; Sun X
    Microbiol Spectr; 2023 Jun; 11(3):e0377722. PubMed ID: 37125917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
    Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
    Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
    Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
    mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
    Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.
    Hu X; Dong R; Huang S; Zeng Y; Zhan W; Gao X; Tian D; Peng J; Xu J; Wang T; Zhang Y; Wang X; Zhang X; Liu J; Guang B; Yang T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0170422. PubMed ID: 37052498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal Inflammation Reversibly Alters the Microbiota to Drive Susceptibility to Clostridioides difficile Colonization in a Mouse Model of Colitis.
    Barron MR; Sovacool KL; Abernathy-Close L; Vendrov KC; Standke AK; Bergin IL; Schloss PD; Young VB
    mBio; 2022 Aug; 13(4):e0190422. PubMed ID: 35900107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota in burned patients with Clostridioides difficile infection.
    Shoaei P; Shojaei H; Siadat SD; Moshiri A; Vakili B; Yadegari S; Ataei B; Khorvash F
    Burns; 2022 Aug; 48(5):1120-1129. PubMed ID: 34924229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection.
    Andersson JA; Peniche AG; Galindo CL; Boonma P; Sha J; Luna RA; Savidge TC; Chopra AK; Dann SM
    mBio; 2020 Mar; 11(2):. PubMed ID: 32156806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
    Tashiro S; Taguchi K; Enoki Y; Matsumoto K
    Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
    Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
    Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
    Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
    PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Liu L; Zhou X; Li B; Cheng F; Cui H; Li J; Zhang J
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820771
    [No Abstract]   [Full Text] [Related]  

  • 19. The microbial metabolite urolithin A reduces
    Ghosh S; Erickson D; Chua MJ; Collins J; Jala VR
    mSystems; 2024 Feb; 9(2):e0125523. PubMed ID: 38193707
    [No Abstract]   [Full Text] [Related]  

  • 20. Repurposing auranofin as a Clostridioides difficile therapeutic.
    Hutton ML; Pehlivanoglu H; Vidor CJ; James ML; Thomson MJ; Lyras D
    J Antimicrob Chemother; 2020 Feb; 75(2):409-417. PubMed ID: 31642901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.